![Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil | International Journal of Impotence Research Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil | International Journal of Impotence Research](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41443-018-0046-2/MediaObjects/41443_2018_46_Fig1_HTML.png)
Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil | International Journal of Impotence Research
![PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Al "filo" del Alprostadil(o) en crema (I): Vitaros / Virirec PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Al "filo" del Alprostadil(o) en crema (I): Vitaros / Virirec](https://1.bp.blogspot.com/-1IMcFh2FVzE/VW2LuLCTmXI/AAAAAAAA63E/MsGGXRIpH_E/s1600/1.png)
PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Al "filo" del Alprostadil(o) en crema (I): Vitaros / Virirec
1 PROSPECT: INFORMAŢII PENTRU UTILIZATOR Vitaros 2 mg/g cremă Alprostadil Citiţi cu atenţie şi în întregime acest prospec
Package leaflet: Information for the user Alprostadil Recordati 2 mg/g cream Alprostadil Read all of this leaflet carefully befo
![Clinical Efficacy and Safety of Vitaros©/Virirec© (Alprostadil Cream) for the Treatment of Erectile Dysfunction - Ignacio Moncada, Béatrice Cuzin, 2015 Clinical Efficacy and Safety of Vitaros©/Virirec© (Alprostadil Cream) for the Treatment of Erectile Dysfunction - Ignacio Moncada, Béatrice Cuzin, 2015](https://journals.sagepub.com/cms/10.5301/uro.5000116/asset/images/large/10.5301_uro.5000116-fig6.jpeg)
Clinical Efficacy and Safety of Vitaros©/Virirec© (Alprostadil Cream) for the Treatment of Erectile Dysfunction - Ignacio Moncada, Béatrice Cuzin, 2015
1 PROSPECT: INFORMAŢII PENTRU UTILIZATOR Vitaros 3 mg/g cremă Alprostadil Citiţi cu atenţie şi în întregime acest prospec
Clinical Efficacy and Safety of Vitaros©/Virirec© (Alprostadil Cream) for the Treatment of Erectile Dysfunction - Ignacio Moncada, Béatrice Cuzin, 2015
RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014 (SALES +6.5%, O
![Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study | International Journal of Impotence Research Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study | International Journal of Impotence Research](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41443-020-00400-9/MediaObjects/41443_2020_400_Fig1_HTML.png)
Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study | International Journal of Impotence Research
![PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Al "filo" del Alprostadil(o) en crema (I): Vitaros / Virirec PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Al "filo" del Alprostadil(o) en crema (I): Vitaros / Virirec](https://3.bp.blogspot.com/-QNmtC-g565U/VW2I4pm0hTI/AAAAAAAA624/Q_0-xWbIGYM/s1600/Imagen3.jpg)